Poly-L-lactic acid

American Journal of Clinical Dermatology

Volumn 5, Issue 5, 2004, Pages 361-366

  Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID;

BIODEGRADABLE IMPLANT; BLEEDING; CELLULITIS; DRUG EFFECT; DRUG TOLERABILITY; ECCHYMOSIS; FACE MUSCLE; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; INFECTION; LIPOATROPHY; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN INDURATION; SKIN NODULE; SKINFOLD THICKNESS; VISUAL ANALOG SCALE;

ADIPOSE TISSUE; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; FACIAL DERMATOSES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LACTIC ACID; POLYMERS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 10644233691     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405050-00010     Document Type: Review

References (13)

1. Moyle G, Sutinen J. Managing HIV lipoatrophy. Lancet 2004 Feb 7; 363 (No. 9407): 412-4
2. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004 Mar; 5 (2): 82-7
3. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002 Nov; 28 (11): 979-86
4. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003 Mar 1: 361 (9359): 726-35
5. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001 Dec 7; 15 (18): 2441-4
6. Boix V. Polylactic acid implants. A new smile for lipoatrophic faces? AIDS 2003 Nov 21; 17 (17): 2533-5
7. Aventis Press Release. FDA Approves SCULPTRATM (Injectable Poly-L-Lactic Acid) [online]. Available from URL: http://www.aventis.com/main/ page.asp?pageid+90014620040803223752 [Accessed 2004 Oct 25]
8. Aventis. Sculptra™/New-Fill™ Product Information [online]. Available from URL: http://www.sculptra.com/global [Accessed 2004 Oct 28]
9. Dermik Laboratories BPU. SCULPTRA™ (injectable poly-L-lactic acid). Prescribing Information. Berwyn, (PA): 2004 Aug
10. US OKs Aventis' Sculptra. PharmaTimes News [Online]. Available from http://www.pharmatimes.com.news/040804f.asp 2004 Aug 4, 2
11. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (NewFill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003 Nov 21; 17 (17): 2471-7
12. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993 Sep; 27 (9): 1135-48
13. Brady JM, Cutright DE, Miller RA, et al. Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res 1973 Mar; 7 (2): 155-66